AKT1 and vitiligo: When PMPP, together with Akt inhibitor IV, was introduced to cells in vitro, tyrosinase activity was inhibited, resulting in a severe decrease in melanin content, suggesting that MITF needs the PI3K pathway and that PMPP is a promising agent for the treatment of vitiligo [301].